Consequently, a major therapeutic approach involves the development of small molecules that competitively bind to this MDM2 pocket, mimicking the essential p53 residues and disrupting the p53–MDM2 complex, which prevents p53 degradation and restores its tumor‐suppressive activities [552, 553]. The gene discussed is TP53; the disease is neoplasm.